Aqneursa (levacetylleucine)

Ataxia-telangiectasia

Also known as IB1001

Manufacturer: IntraBio
Regulatory submission: sNDA submitted March 2026 and approved September 2026
Launch: Commercially available at approval in September 2026
Last updated: October 2, 2026

Section

Product information and disease description Product description

Product information

149 evidence topics · 67 sources

Generic, brand name and therapeutic class of product7 evidence topics · 8 sources
Dosage forms and strengths6 evidence topics · 3 sources
Average sales price and wholesale acquisition cost8 evidence topics · 9 sources
American hospital formulary service (AHFS), or other drug classification4 evidence topics · 4 sources
Indication4 evidence topics · 4 sources
Pharmacology36 evidence topics · 22 sources
Contraindications/Warnings/Precautions/Adverse effects19 evidence topics · 5 sources
Special populations11 evidence topics · 3 sources
Drug/Drug, drug/disease interactions9 evidence topics · 5 sources
Dosing and administration11 evidence topics · 3 sources
Access and distribution17 evidence topics · 15 sources
Co-prescribed/Concomitant therapies5 evidence topics · 4 sources
Product comparison12 evidence topics · 19 sources

Effect of levacetylleucine on quality measures

No evidence found.